Jane Adam

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study.

Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study.

Journal: BMJ open
Published: December 07, 2024

Response to: 'How effective are selection methods in medical education? A systematic review'.

Response to: 'How effective are selection methods in medical education? A systematic review'.

Journal: Medical education
Published: March 01, 2017

NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.

NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.

Journal: The Lancet. Oncology
Published: October 04, 2016

NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.

NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.

Journal: The Lancet. Oncology
Published: February 01, 2016

Predictors of professional behaviour and academic outcomes in a UK medical school: A longitudinal cohort study.

Predictors of professional behaviour and academic outcomes in a UK medical school: A longitudinal cohort study.

Journal: Medical teacher
Published: February 11, 2015

NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.

NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.

Journal: The Lancet. Oncology
Published: December 16, 2014

NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma.

NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma.

Journal: The Lancet. Oncology
Published: October 21, 2014

NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

Journal: The Lancet. Oncology
Published: May 28, 2013

NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.

NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.

Journal: The Lancet. Oncology
Published: May 28, 2013

NICE guidance on ipilimumab for previously treated advanced melanoma.

NICE guidance on ipilimumab for previously treated advanced melanoma.

Journal: The Lancet. Oncology
Published: February 13, 2013

NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

Journal: The Lancet. Oncology
Published: February 13, 2013

Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.

Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.

Journal: The Lancet. Oncology
Published: October 02, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026